These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16239913)

  • 21. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
    Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
    Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting multiple myeloma cells and their bone marrow microenvironment.
    Pagnucco G; Cardinale G; Gervasi F
    Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
    Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards a new age in the treatment of multiple myeloma.
    Piazza FA; Gurrieri C; Trentin L; Semenzato G
    Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
    Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
    Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
    Podar K; Richardson PG; Chauhan D; Anderson KC
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biology and bioinformatics of myeloma cell.
    Abroun S; Saki N; Fakher R; Asghari F
    Lab Hematol; 2012 Dec; 18(4):30-41. PubMed ID: 23253865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
    Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
    Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.
    Akhtar S; Ali TA; Faiyaz A; Khan OS; Raza SS; Kulinski M; Omri HE; Bhat AA; Uddin S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular resistance mechanisms with impact on the therapy of multiple myeloma.
    Gieseler F; Nüssler V
    Leukemia; 1997 Dec; 11 Suppl 5():S1-4. PubMed ID: 9436930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma.
    Neri P; Bahlis NJ
    Curr Cancer Drug Targets; 2012 Sep; 12(7):776-96. PubMed ID: 22671924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
    Yen CH; Hsiao HH
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting signaling pathways in multiple myeloma.
    Federica C; Antonio P; Guido T; Mario B
    Curr Pharm Biotechnol; 2006 Dec; 7(6):407-13. PubMed ID: 17168656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance.
    Shain KH; Landowski TH; Dalton WS
    Curr Opin Oncol; 2000 Nov; 12(6):557-63. PubMed ID: 11085455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
    Manni S; Carrino M; Semenzato G; Piazza F
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic Features of Multiple Myeloma.
    El Arfani C; De Veirman K; Maes K; De Bruyne E; Menu E
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apoptotic signaling in multiple myeloma: therapeutic implications.
    Chauhan D; Hideshima T; Anderson KC
    Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.